The pharmaceutical industry is facing challenges amidst waves of tariffs, with observers pointing to the potential impact of intellectual property (IP) on transactions and deal-making, particularly for India. While tariffs have dominated the conversation, the role of IP as a negotiating tool is gaining importance, according to economists and industry consultants who have been monitoring trade and IP relationships between countries.
The upcoming release of the annual Special 301 report by the office of the United States Trade Representative (USTR) is adding to the uncertainty surrounding the pharmaceutical industry. The report evaluates how trading partners handle IP issues across various sectors, with a deadline for submissions and hearings that recently ended.
India has been consistently included on the ‘priority watch list’ in previous Special 301 reports, which triggers increased bilateral attention and potential action. While retaliatory actions have not been significant in the past, the current trade environment could lead to changes, especially with the strong focus on IP in the US President’s trade policy.
The role of IP in trade negotiations was further emphasized in a Presidential memorandum on ‘Reciprocal Trade and Tariffs’, which highlights the evaluation of barriers, including IP protections. The report is due on April 1, with a ‘Fair and Reciprocal Plan’ expected by August 12.
Concerns within the domestic industry revolve around potential IP concessions to US drug-makers, which could impact India’s IP framework and access to affordable medicines. The Indian Pharmaceutical Alliance, representing top Indian drug-makers, regularly participates in the Special 301 process to address IP-related issues and advocate for the removal of India from the ‘priority watch list’.
India’s IP regime has prioritized equity and affordability, particularly in the healthcare sector, by integrating flexibilities under the TRIPS Agreement. However, there are concerns that increased focus on IP in trade negotiations could impact the balance between innovation and access to medicines.
As the release of the Special 301 report approaches, the pharmaceutical industry in India is bracing for potential changes in the IP landscape that could have far-reaching implications for trade relations and access to healthcare.
